Daniel H. Cooper

Daniel H. Cooper

Auto-generated profile, based on publicly available information

Daniel H. Cooper

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
DCDaniel H. Cooper
Daniel H. Cooper
RRRanuk Ramachandra
Ranuk Ramachandra
FCFelicia Ceban
Felicia Ceban
JVJoshua Daniel Di Vincenzo
Joshua Daniel Di Vincenzo
GRGreg Rhee
Greg Rhee
RMRoger McIntyre
Roger McIntyre

4 June 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
DCDaniel H. Cooper
Daniel H. Cooper
NANicky Akbarian
Nicky Akbarian
SAShawn D. Aaron
Shawn D. Aaron
VLVanessa Luks
Vanessa Luks
TKTetyana Kendzerska
Tetyana Kendzerska

1 May 2021 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
HGHartej Gill
Hartej Gill
BGBarjot Gill
Barjot Gill
OLOrly Lipsitz
Orly Lipsitz
NRNelson B. Rodrigues
Nelson B. Rodrigues
DCDanielle S. Cha
Danielle S. Cha
RMRoger McIntyre
Roger McIntyre

1 September 2014 in Economics Letters
Verified
Journal Article
Closed access
ABAnat Bracha
Anat Bracha
DCDaniel Cooper
Daniel Cooper

1 March 2019 in JACC
Verified
Journal Article
Closed access
JBJose Ernesto Betancourt
Jose Ernesto Betancourt
ANAmit Noheria
Amit Noheria
DCDaniel Cooper
Daniel Cooper
GOGeoffrey Orme
Geoffrey Orme
SSSandeep Sodhi
Sandeep Sodhi
PCPhillip Cuculich
Phillip Cuculich

22 November 2015 in Echocardiography
Verified
Journal Article
Open access
PDF file
RRRavi Rasalingam
Ravi Rasalingam
MHMark R. Holland
Mark R. Holland
DCDaniel H. Cooper
Daniel H. Cooper
ENEric Novak
Eric Novak
MRMichael W. Rich
Michael W. Rich
JPJulio E. Pérez
Julio E. Pérez
The purpose of this study was to determine whether resting myocardial deformation and rotation may be altered in diabetic patients with significant epicardial coronary artery disease (CAD) with normal left ventricular ejection fraction. A prospective observational study. Diagnosis of epicardial CAD in patients with diabetes. Eighty-four patients with diabetes suspected of epicardial CAD scheduled for cardiac catheterization had a resting echocardiogram performed prior to their procedure. Echocardiographic measurements were compared between patients with and without significant epicardial CAD as determined by cardiac catheterization. Measurement of longitudinal strain, strain rate, apical rotation, and rotation rate, using speckle tracking echocardiography. Eighty-four patients were studied, 39 (46.4%) of whom had significant epicardial CAD. Global peak systolic apical rotation was significantly increased (14.9 ± 5.1 vs. 11.0 ± 4.8 degrees, P < 0.001) in patients with epicardial CAD along with faster peak systolic apical rotation rate (90.4 ± 29 vs. 68.1 ± 22.2 degrees/sec, P < 0.001). These findings were further confirmed through multivariate logistic regression analysis (global peak systolic apical rotation OR = 1.17, P = 0.004 and peak systolic apical rotation rate OR = 1.05, P < 0.001). Patients with diabetes with significant epicardial CAD and normal LVEF exhibit an increase in peak systolic apical counterclockwise rotation and rotation rate detected by echocardiography, suggesting that significant epicardial CAD and its associated myocardial effects in patients with diabetes may be detected noninvasively at rest.